| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04238390 Details | 2022-05-19 Interventional | 3 | 0 | Ceftolozane Ceftolozane, ta… Meropenem Tazobactam Bacteremia Sepsis Bacteremia Caus… | The decision to withdraw the study was made due to delayed logistics of the supply chain of
ceftolozane-tazobactam along with the immense complexities of conducting clinical research felt
because of the COVID-19 pandemic. - | |||
| NCT02715466 Details | 2022-05-19 Interventional | 4 | 167 | Pharmaceutical … Hypovolemia | recommended by DSMB - | |||
| NCT04996667 Details | 2022-05-18 Interventional | 2 | [4 Refs] | 0 | Nitric Oxide Embolism Pulmonary Embol… Pulmonary Embol… | no sponsor support - | ||
| NCT01730313 Details | 2022-05-18 Interventional | 2 | 0 | Phenytoin Pyridoxine Valproic Acid Vitamin B 6 Nodding Syndrom… Syndrome | Did not get approval from the collaborating partners in-country - | |||
| NCT00669669 Details | 2022-05-18 Interventional | 1/2 | 12 | Carmustine Lenograstim O(6)-benzylguan… Plerixafor Temozolomide Glioblastoma Glioma Gliosarcoma | Terminated due to loss in funding. - | |||
| NCT04150562 Details | 2022-05-17 Interventional | 2 | 2 | Avelumab Carcinoma Carcinoma, Rena… Kidney Neoplasm… Clear-Cell Rena… | This study was terminated early due to manufacturer withdrawal of support (study medication)
due to lack of enrollment. - | |||
| NCT02801097 Details | 2022-05-17 Interventional | 1 | 28 | Irinotecan Neoplasms Advanced Cancer Malignant Solid… Metastatic Canc… | Sufficient patients enrolled to end study - | |||
| NCT01285557 Details | 2022-05-17 Interventional | 3 | 361 | Cisplatin Fluorouracil Tegafur Stomach Neoplas… Metastatic Diff… | Due to significant changes in investigational and clinical practice landscape of frontline
advanced gastric cancer, which challenged viability of trial and increased use of modified
chemotherapeutic triplets led to slow participant accrual in study. Enrollment closure and study termination was due to significant changes in investigational and clinical practice landscape of frontline advanced gastric cancer, which challenged viability of trial and increased use of modified chemotherapeutic triplets led to slow participant accrual in the study. The decision to halt further accrual was not based on any safety or study quality concerns. | |||
| NCT04368364 Details | 2022-05-16 Interventional | 4 | 3 | Bupivacaine Morphine Ropivacaine Pain, Postopera… | Study was stopped early due to a conflicting study in the same patient population at the study
location. - | |||
| NCT04115748 2019-001996-35 Details | 2022-05-16 Interventional | 3 | 67 | Adalimumab Arthritis Arthritis, Psor… Psoriatic Arthr… | Development program terminated Due to early termination of the study and insufficient number of participants enrolled, all the hypothesis testing performed and the p values reported were nominal. Therefore, the results need to be interpreted with caution. | |||
| NCT03597035 Details | 2022-05-16 Interventional | 4 | 8 | Spironolactone Atherosclerosis Hyperkalemia Type2 Diabetes | The study could not enroll patients owing to the inclusion exclusion criteria - | |||
| NCT03367819 2017-002846-61 Details | 2022-05-16 Interventional | 1/2 | 44 | Cemiplimab Carcinoma, Non-… Non-small Cell … Prostate Cancer | The study was stopped after interim analysis indicated that overall result was not sufficient
to satisfy per-protocol criteria to move forward in metastatic, castration-resistant prostate
cancer (mCRPC) and non-small cell lung cancer (NSCLC) cohorts. The study was terminated after the interim analysis of the primary endpoint. Few planned outcome measures per-protocol were not analyzed because overall efficacy results were not sufficient at the time of interim analyses of both the cohorts. | |||
| NCT03655821 Details | 2022-05-13 Interventional | 4 | 81 | Pemetrexed Carcinoma, Non-… Lung Neoplasms Mesothelioma Mesothelioma, M… Non Small Cell … | 81 patients included, difficult inclusion and full inclusion would not change the results - | |||
| NCT02060487 2013-004362-34 Details | 2022-05-13 Interventional | 4 | 385 | Citric Acid Sildenafil Citr… Sodium Citrate Familial Primar… Hypertension Pulmonary Arter… | Study was terminated by Sponsor at recommendation of Data Monitoring Committee after completion
of first interim analysis as primary objective was met. Study was terminated by Sponsor at recommendation of Data Monitoring Committee after completion of first interim analysis as primary objective was met. For OS and clinical worsening(CW) endpoints, significance level was adjusted to allow for interim analysis. Hence 99.7% CIs were presented instead of 95% CIs. 80mg vs 5mg comparison for OS was primary and it was key secondary for CW. CIs for other dose comparisons for these endpoints were nominal. P-values and CIs for other endpoints were nominal | |||
| NCT01487174 Details | 2022-05-13 Interventional | 3 | 8 | Erlotinib Hydro… Carcinoma, Non-… | Kadmon has made a business decision to terminate the study due to slow enrollment. Note the
decision to terminate the study was not related to safety issues - | |||
| NCT03192345 2018-001113-32 Details | 2022-05-12 Interventional | 1 | 161 | Cemiplimab Neoplasms Malignant Solid… | Occurrence of objective responses in multiple indications in the Phase 1b was not enough to
warrant further exploration in view of competitive landscape and some toxicity (mostly bleeding
events). - | |||
| NCT03628391 Details | 2022-05-11 Interventional | 3 | 142 | Haloperidol Haloperidol dec… Cognitive Dysfu… Critical Illnes… Delirium Cognitive Decli… Cognitive Impai… Intensive Care … | The study was stopped because of futility of being able to reach a one-day difference between
treatment groups in the primary outcome of DCFD in the intended sample size. - | |||
| NCT02121405 Details | 2022-05-11 Interventional | 3 | - | Capecitabine Oxaliplatin Colorectal Neop… Colorectal Neop… Effects of Chem… Effects of Radi… Surgery | DSMB stopped this trial due to the difference of 3-year DFS's rate between two groups more than
5% at the interim analysis in July 2021. - | |||
| NCT01744912 Details | 2022-05-11 Interventional | 1 | 10 | Lenalidomide Leukemia, Lymph… Lymphoma Lymphoma, Mantl… Waldenstrom Mac… B-cell Lymphoma… Chronic Lymphoc… Mantle Cell Lym… Marginal Zone L… Non-Hodgkins Ly… Small Lymphocyt… Waldenstrom's M… | Sponsor's decision - | |||
| NCT05003102 Details | 2022-05-10 Interventional | 4 | 0 | Dexmedetomidine Fentanyl Critical Illnes… Delirium Sedation Compli… | No enrollment, IRB closed - |